THIS WEEK'S FEATURE
As managing director, life sciences specialty services at BDO, the global professional services firm, Susan Linna has more than 25 years of drug, vaccine and biologic development experience, 13 of which were at a Fortune 100 pharmaceutical company, and 13 years in biotechnology.
Closely-held CellMax Life has developed FirstSightCRC, the first blood test to identify precancerous adenomas, with accuracy similar to colonoscopies, when prevention of colorectal cancer (CRC) is possible.
With the FDA’s 510(k) clearance of its PURE EP System in August 2018 and first successful patient cases, BioSig (NASDAQ:BSGM) is advancing its vision to improve medicine through biomedical signal processing.
Closely-held NuPulseCV is enrolling patients with advanced heart failure in a feasibility study with its intravascular ventricular assist system (iVAS), a minimally invasive heart pump designed to allow patients to be discharged from hospital and resume their daily activities.
Closely-held Vessi Medical wants to change the standard of care for superficial bladder cancer by using a surface cryotherapy approach in a minimally invasive in-office treatment alternative to surgery.